Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Luteinizing Hormone Receptor Is Expressed in Testicular Germ Cell Tumors: Possible Implications for Tumor Growth and Prognosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Evaluation of Circulating miRNA Biomarkers of Testicular Germ Cell Tumors during Therapy and Follow-up-A Copenhagen Experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Predicting visual acuity deterioration and radiation-induced toxicities after brachytherapy for choroidal melanomas

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. The tolerance of anisometropia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Isolated Ocular Sarcoidosis Mimicking Ring Melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Uveal melanoma (UM) is the most common intraocular malignancy in adults and shows a high rate of metastatic spread. As randomized clinical trials with immune checkpoint inhibitors (ICI) have not been performed in patients with metastatic UM, we analyzed the real-world outcomes in a nationwide population-based study. Clinical data of patients with UM were extracted from the Danish Metastatic Melanoma database, a nationwide database containing unselected records of patients diagnosed with metastatic melanoma in Denmark. Survival before (pre-ICI, n = 32) and after (post-ICI, n = 94) the approval of first-line treatment with ICI was analyzed. A partial response to first-line treatment was observed in 7% of patients treated with anti-programmed cell death protein (PD)-1 monotherapy and in 21% with combined anti-cytotoxic T lymphocyte antigen (CTLA)-4 plus anti-PD-1 therapy. Median progression-free survival was 2.5 months for patients treated in the pre-ICI era compared to 3.5 months in the post-ICI era (hazard ratio (HR) 0.43; 95% confidence interval (CI) 0.28-0.67; p < 0.001). The estimated one-year overall survival rate increased from 25.0% to 41.9% and the median overall survival improved from 7.8 months to 10.0 months, respectively (HR 0.52; 95% CI 0.34-0.79; p = 0.003). Thus, the introduction of ICI as first-line treatment appears to have significantly improved the real-world survival of patients with metastatic UM, despite relatively low response rates compared to cutaneous melanoma. With the lack of therapies proven effective in randomized trials, these data support the current treatment with ICI in patients with metastatic UM.

Original languageEnglish
JournalCancers
Volume11
Issue number10
ISSN2072-6694
DOIs
Publication statusPublished - 3 Oct 2019

ID: 58521057